Baader Bank Aktiengesellschaft Takes $503,000 Position in Mirum Pharmaceuticals, Inc. $MIRM

Baader Bank Aktiengesellschaft purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 6,895 shares of the company’s stock, valued at approximately $503,000.

Other hedge funds also recently bought and sold shares of the company. CWM LLC boosted its holdings in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the last quarter. Legal & General Group Plc lifted its position in Mirum Pharmaceuticals by 0.4% during the second quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock worth $2,189,000 after buying an additional 176 shares in the last quarter. MCF Advisors LLC boosted its stake in Mirum Pharmaceuticals by 76.4% during the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after buying an additional 185 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in Mirum Pharmaceuticals by 2.2% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after buying an additional 215 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after buying an additional 243 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 2.1%

Shares of NASDAQ MIRM opened at $102.01 on Friday. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $5.24 billion, a PE ratio of -118.61 and a beta of 0.49. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $105.74. The stock has a fifty day simple moving average of $85.68 and a 200-day simple moving average of $75.40.

Insider Activity at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the transaction, the chief executive officer owned 160,294 shares of the company’s stock, valued at approximately $16,558,370.20. This trade represents a 5.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 968 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the sale, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. This trade represents a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 45,136 shares of company stock valued at $4,352,029. 14.36% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MIRM. Evercore reissued an “outperform” rating and set a $101.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. HC Wainwright boosted their target price on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a report on Monday, January 26th. Raymond James Financial restated a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Morgan Stanley upped their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Finally, JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $107.25.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.